Hisamitsu Pharmaceutical Co., Inc. provided consolidated earnings guidance for the fiscal year ending February 29, 2024. For the period, the company expected net sales of JPY 132,300 million, operating profit of JPY 11,800 million, profit attributable to owners of parent of JPY 10,600 million and profit per share of JPY 136.34.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3,779 JPY | +1.86% | +1.61% | -12.34% |
Apr. 11 | Hisamitsu Pharmaceutical Attributable Profit Up 19% in Fiscal 2024 | MT |
Jan. 12 | Hisamitsu Pharmaceutical Lifts Fiscal-Year Targets as Nine-Month Profit, Net Sales Rise | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-12.34% | 1.82B | |
+25.93% | 661B | |
+26.74% | 566B | |
-6.64% | 352B | |
+18.99% | 332B | |
+3.23% | 283B | |
+13.43% | 231B | |
+4.71% | 200B | |
-9.53% | 195B | |
-4.14% | 145B |
- Stock Market
- Equities
- 4530 Stock
- News Hisamitsu Pharmaceutical Co., Inc.
- Hisamitsu Pharmaceutical Co., Inc. Provides Consolidated Earnings Guidance for the Fiscal Year Ending February 29, 2024